<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00987610</url>
  </required_header>
  <id_info>
    <org_study_id>G-FORCE</org_study_id>
    <nct_id>NCT00987610</nct_id>
  </id_info>
  <brief_title>Guidewire for Chronic Total Occlusion</brief_title>
  <acronym>G-FORCE</acronym>
  <official_title>Multicenter Prospective Randomized Study of First-choice Guidewires in Percutaneous Coronary Intervention for Chronic Total Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tokai University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaneka Pharma America LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asahi Intech</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Terumo Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Japan Lifeline</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tokai University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Under the circumstances that appropriate first-choice guidewires for percutaneous coronary
      intervention (PCI) for chronic total occlusion (CTO) have yet to be established, the
      objective of this study is to determine appropriate first-choice guidewires. G-FORCE study is
      a prospective multicenter randomized study between normal (distal tip size 0.014 inch) and
      slender (distal tip size 0.010 inch or less) guidewires. Primary end point is lesion
      penetration rate of the first choice guidewire.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background. Although the success rate of PCI for CTO is yet to reach a satisfactory level,
      prognoses have been improved in successful cases. The greatest challenge is the passage of
      the guidewire and a variety of new approaches including a parallel wire technique and a
      retrograde approach have been reported. However, the fundamental question of what type of
      guidewire is the most appropriate as a first-choice guidewire has not been answered.Tapered
      guidewires have recently been reported to be useful for CTO lesions. In addition, a
      multicenter prospective registry indicates the effectiveness of 0.010-inch guidewires
      (PIKACHU registry, personal communication). Its mechanism is associated with micro-channels
      ranging from 100 to 300 μm in size in CTO lesions. If 250 μm micro-channels are present in
      60% of CTO lesions, a 0.010-inch (equivalent to 250 μm) guidewire theoretically can pass
      through the lesion at the probability of 60%, and this assumption consists with the findings
      of the PIKACHU study. This idea also suggests that a 0.014-inch (350 μm) guidewire is
      unlikely to pass through lesions.

      Based on the above, a hypothesis has been formulated that a guidewire with a small tip should
      be selected as a first-choice guidewire for CTO lesions. In this study, patients will be
      prospectively randomized to slender guidewires or standard 0.014-inch guidewires to determine
      appropriate first-choice guidewires.

      Objective. To determine appropriate first-choice guidewires.

      Design. Prospective multicenter randomized controlled trial

      Methods. The first choice guidewire to treat CTO lesion was randomly assigned to normal group
      (distal tip size 0.014 inch) or slender group (distal tip size 0.010 inch or less). The
      primary passage must be performed with antegrade approach.

      Primary endpoint. Lesion penetration rate of a first-choice guidewire

      Power calculation. The PIKACHU registry indicates a 0.010 guidewire passes through a lesion
      with a success rate of 60%. Assuming the penetration rate of a 0.014 guidewire is 40%, a
      necessary number of patients would be 260 for a two-sided test with 90% power and
      significance level of 0.05. Assuming the dropout rate is approximately 10%, the target sample
      size would be 290 patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lesion penetration rate of a first-choice guidewire</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful PCI rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Types of guidewires successfully passing through the lesion</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardio-cerebral events (MACCEs: total death, MI, stroke, and all revascularization procedures)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Coronary Occlusion</condition>
  <arm_group>
    <arm_group_label>slender guidewire</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous coronary intervention (PCI) using guidewires with small distal tip equal to 0.010 inch or less</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal guidewire</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous coronary intervention (PCI) using guidewires with normal distal tip equal to 0.014 inch</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention (PCI)</intervention_name>
    <description>PCI for chronic total occlusion is performed using either arm of guidewire</description>
    <arm_group_label>slender guidewire</arm_group_label>
    <arm_group_label>normal guidewire</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic total occlusion (CTO) lesion in native coronary artery

          -  De novo lesion

          -  Elective procedure

        Exclusion Criteria:

          -  No indication of PCI

          -  Prior failed lesion

          -  Restenotic or in-stent restenotic lesion

          -  Vein or arterial grafts

          -  Younger than 20 years old

          -  Pregnant woman

          -  Patients who gave no informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuji Ikari, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tokai University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kazuaki Mitsudo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kurashiki Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Osamu Kato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toyohashi Heart Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shigeru Saito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shonan Kamakura General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toyohashi Heart Center</name>
      <address>
        <city>Toyohashi</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jikei University Kashiwa Hospital</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mie Heart Center</name>
      <address>
        <city>Taki-gun</city>
        <state>Mie</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sendai Kousei Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku Koseinenkin Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansan Rosai Hospital</name>
      <address>
        <city>Amagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aomori Central Hospital</name>
      <address>
        <city>Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsuchiya General Hospital</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokura Kinen hospital</name>
      <address>
        <city>Kitakyusyu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takahashi Hospital</name>
      <address>
        <city>Kobe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurune University Hospital</name>
      <address>
        <city>Kurume</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Prefectual Central Hospital</name>
      <address>
        <city>Morioka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine</name>
      <address>
        <city>Nishinomiya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Omori Medical Hospital Center</name>
      <address>
        <city>Ota</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoshi General Hospital</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Higashi Tokushukai</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokeidai Hospital</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka General Hospital</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tenri Hospital</name>
      <address>
        <city>Tenri</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University</name>
      <address>
        <city>Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Sakae Kyosai Hospital</name>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>September 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2009</study_first_posted>
  <last_update_submitted>May 1, 2015</last_update_submitted>
  <last_update_submitted_qc>May 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tokai University</investigator_affiliation>
    <investigator_full_name>Yuji Ikari</investigator_full_name>
    <investigator_title>Professor, Department of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>chronic total occlusion</keyword>
  <keyword>guidewire</keyword>
  <keyword>Angioplasty, Transluminal, Percutaneous Coronary</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Percutaneous Coronary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Occlusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

